Capecitabine
Efficacy and Safety
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversitySmall moleculeActive
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 89/ 100
Competitive context
8 Active assets in the Efficacy and Safety cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Carboplatin Women's Hospital School Of Medicine Zhejiang University | Phase 4 | BB |
Huazhi Rougan Granule Shandong New Time Pharmaceutical Co., LTD | Phase 4 | BB |
Inno-206 Women's Hospital School Of Medicine Zhejiang University | Phase 4 | BB |
Rivoceranib Rongjie Tao | Phase 2 | B |
Catequentinib Sun Yat-sen University | Phase 2 | CCC |
View all 14 →
Same molecule, other indications
Capecitabine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →